Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Country-specific medical scientific information for Healthcare Professionals.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
A knowledge hub developed to provide information and education in oncology for healthcare professionals.
Listen to this podcast on our real-world study of first-line afatinib* followed by osimertinib
NSCLC in focus: information and educational resources
Learn more about our MDM2-p53 antagonist^ and other investigational compounds
*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
^This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
